Cited by 362Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Open access

Oxnard, Geoffrey R., Lo, Peter C., Nishino, Mizuki, Dahlberg, Suzanne E., Lindeman, Neal I., Butaney, Mohit, Jackman, David M., Johnson, Bruce E., Jänne, Pasi A.·2013·Journal of Thoracic Oncology

DOI 10.1097/jto.0b013e3182779d18PMC PMC3549533

Open this paper in CoChat — free account

Abstract

Introduction Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies.Methods NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board. Cancers with exon 20 insertions were indentified, sequences were characterized, and effectiveness of different treatment regimens was reviewed retrospectively. Clinical characteristics and survival were compared with cancers harboring common EGFR mutations and cancers with wild-type EGFR.Results One thousand eighty-six patients underwent EGFR genotyping from 2004 to 2012. Twenty seven (2.5%) harbored exon 20 insertions, making up 9.2% of all cancers with documented EGFR mutations. Compared with wild-type cancers, those with exon 20 insertions were more commonly found in never-smokers and Asian patients. Insertion sequences were highly variable, with the most common variant (V769_D770insASV) making up only 22% of cases. Median survival of patients with exon 20 insertions was 16 months, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations.Conclusions Patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations but a poorer prognosis. The prevalence of this subset of NSCLC is similar to that of other genotype-defined subsets of lung adenocarcinoma (e.g. those with BRAF mutations, HER2 insertions, ROS1 rearrangements) and is a population of interest for trials of new targeted therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e3182779d18

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“The identification of epidermal growth factor receptor (EGFR) mutations in a subset of non–small-cell lung cancer (NSCLC) and their association with durable responses to EGFR tyrosine kinase inhibitors (TKIs) has transformed our approach towards the use of targeted therapies in treating lung cancer.(1,2) This initial…”
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220

Show all 32 references

Sorted by citations

Items 301–362 of 362

EGFR Resistance
Bourdeanu, L., Liu, E. Y., Brint, S., & Langdon, D. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_4 · Cited by 1
Uncommon EGFR-Mutant NSCLC—One Drug Does Not Fit All
Wang, Y., & Arulananda, S. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100477 · Cited by 1
[Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].
Xu, M., Luo, J., & Xu, R. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.101.05 · Cited by 1
[Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non-small Cell Lung Cancer].
Wang, Y., & Chu, T. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.06 · Cited by 1
Ultra-rapid Idylla™ EGFR mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer
Qiu, T., Zhang, F., Zheng, B. J., Feng, Z., Li, W., Hua, Z., Chu, L., & Ying, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1064487 · Cited by 1
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
Kaakour, D., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s454736 · Cited by 1
EGFR Targeted Therapy
Noor, Z. S., & Goldman, J. W. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_1 · Cited by 1
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
Matsuura, S., Morikawa, K., Ito, Y., Kagoo, N., Kubota, T., Ichijo, K., Mochizuki, E., Uehara, M., Harada, M., Tsukui, M., et al. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101236 · Cited by 1
A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report
Liang, P., Qi, L., Guo, T., You, X., & Cui, C. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.014 · Cited by 1
Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing
Moore, D. A., Balbi, K. J., Poskitt, B., & Bennett, P. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207643 · Cited by 1
Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab
de la Fuente, E. C., Olmedo, M. E., Orejana, I., Berlinches, A. B., Rueda, A. G., Lage, Y., & Garrido, P. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100145 · Cited by 1
Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer
Jeong, B., & Um, S. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.37 · Cited by 1
Predictive biomarkers in diffuse gliomas and non-small cell lung cancer
Merkkiniemi, K. (2015) · Työväentutkimus Vuosikirja
Strategy on Patients with EGFR Mutation
Früh, M., Zhou, Q. H., Leung, L. K. S., & Mok, T. S. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-06062-0_9
Molecular pathology in lung cancer
Cooper, W. A., & O’Toole, S. A. (2013) · Cancer Forum
Traitement des progressions tumorales dans le cancer du poumon muté EGFR : à propos d'une cohorte de patients métastatiques suivis à l'Institut Bergonié
Domblides, C. (2015) · HAL
EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in
Kondo, C., Shimizu, J., Horio, Y., Yoshida, K., & Hida, T. (2014)
Mechanisms of Acquired Resistance to Targeted Therapy in NSCLC: Role of Repeat Biopsy and Nursing Considerations
Duffield, E. (2019) · Springer eBooks · doi:10.1007/978-3-030-16550-5_6
[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
Zhou, W., Zhang, W., & Han, B. (2020) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2020.02.07
Understanding the response to EGFR targeting therapy in non-small-cell lung cancer using -omics approach
Tran, Y. Z. (2020) · Figshare
US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy
Yu, M., Tadesse, S., & Wang, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc214.pub2
Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response
Pancrazzi, A., Ognibene, A., Moncada, A., & Torre, V. (2021) · Global Medical Genetics · doi:10.1055/s-0041-1732481
EGFR L858R Mutation Combined with EGFR Exon 20 Insertion Mutation in Lung Adenocarcinoma: A Case Report and Literature Review
朱, 文. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111792
Will CHRYSALIS turn into a butterfly?
Fuereder, T. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100421
Les cancers bronchiques non à petites cellules EGFR-mutés
Baldacci, S., Gervais, R., & Cortot, A. B. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30054-x
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations
Addeo, A. (2022) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2022.12.071
Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2
Cui, Y., Wang, R., Wei, Y., Hou, F., Li, H., Jiang, Y., Sun, Y., Fu, S., Zuo, L., Wang, X., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117202
Unique natural history of an EGFR mutated adenocarcinoma
Okauchi, S., & Satoh, H. (2023) · Klinicka onkologie · doi:10.48095/ccko202371
Data from Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
(2023) · doi:10.1158/2159-8290.c.6549370.v1
EGFR Exon 20 Insertion Mutations: CT Characteristics and Clinicopathologic Features in Non-Small Cell Lung CancerPreprint
Pang, L., Huang, A., Xie, M., Ma, X., Deng, H., Gao, J., Wu, C., Song, J., Zhang, X., Wang, S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2886639/v1
Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
Liao, Y.-T., Wang, L., Sun, R.-L., Yeh, Y., Huang, H.-C., Shen, C., Tseng, Y.-H., Hsiao, T.-H., Chao, H., Luo, Y., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04921-w
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience
Andrikou, K., Ulivi, P., Petracci, E., Azzali, I., Bertolini, F., Alberti, G., Bettelli, S. R., Calistri, D., Chiadini, E., Capelli, L., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14101024
Anti-Resistant Strategies: Icotinib Derivatives as Promising Non-Small Cell Lung Cancer Therapeutics
Zhao, Z., Du, Y., & Chen, X. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096302595240605114828
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
Yoh, K., Azuma, K., Hayashi, H., Nishio, M., Chikamori, K., Ichihara, E., Watanabe, Y., Asato, T., Kitagawa, T., Fram, R. J., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02588-y · Cited by 1
A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer
Hanley, M. J., Zhang, S., Pavlakis, N., Soo, R. A., van der Wekken, A. J., Ganju, V., Piña, A., Dong, Q., & Gupta, N. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1500
Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions
Wang, K.-Y., Chang, S.-C., Wei, Y., Hung, J.-C., Chen, C., & Chang, C. (2025) · Current Oncology · doi:10.3390/curroncol32030174
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis
Liu, K., Li, H., Tan, Q.-Q., Jiang, T., Peng, K., Chen, H.-J., Zhou, Q., Zhang, X., Zheng, Z., Chen, S., et al. (2025) · Science Progress · doi:10.1177/00368504251325406
Effects of antihypertensive drugs on the metabolism of mobocertinib in rats both in vitro and in vivo
Yi, D., Ye, J., Lu, Z., Lu, L., Qi, T., Luo, T., Peng, X., Mamun, A. A., Zhou, Q., Chen, D., et al. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100094
WITHDRAWN: Production, Purification, and Crystallization of Recombinant Epidermal Growth Factor Receptor Tyrosine Kinase Domain (EGFR-TKD) for Drug Screening ApplicationsPreprint
Topalan, E., Ciftci, H. I., & DeMi̇rci̇, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.02.657332
Efficacy of chemotherapy plus immunotherapy in advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations: A retrospective comparative study
Zhao, Y., Yao, X., Li, R., Dong, X., Li, Y., & Li, Y. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.09.001
Reversed phase HPLC analysis of mobocertinib and its impurities and studies on the structure and biological activity of a new degradation product
Ni, R., Qin, J., Wu, W., Xu, J., Luo, Q., & Cai, L. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1659507
Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I
Vu, H. T., Nguyen, H. T. T., Ta, T. V., Truong, C. M., Xuan, T., Nguyễn, A. T., Nguyen, C. V., Nguyen, H. T. T., Doan, T. T., Vu, T. T., et al. (2025) · Cancer Control · doi:10.1177/10732748251386133
Additional file 4 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915426
Additional file 2 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915417
Additional file 1 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915414
Additional file 3 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915420
Additional file 1 of Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Production, Purification, and Initial Crystallization of Recombinant Epidermal Growth Factor Receptor Tyrosine Kinase Domain (EGFR-TKD) as a Structural Basis for Future Drug Screening Studies
Topalan, E., Ciftci, H. I., & DeMi̇rci̇, H. (2026) · Türk Tarım ve Doğa Bilimleri Dergisi · doi:10.30910/turkjans.1805082
Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia
Balea, B. C., Quintela, M. E. L., Manrique, M. C. A., Raposeiras, C. A., García, J., Afonso, F. J. A., Fernández-Bruno, M., Núñez, N. F., der Schoot, R. R. V., & Couto, L. S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1677766
Rôle des calpaïnes extracellulaires dans la progression des adénocarcinomes lépidiques
Ruppert, A.-M. (2015) · theses.fr (ABES) · doi:10.70675/6082601cze5b6z41e9zb588zf90c85ff07c9
Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR
Baldacci, S. (2017) · doi:10.70675/ea435494z4946z4d12za5f5zd338f77b537b
Advances in Targeted Therapy for EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer
苗, 贤. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641492
Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data
Waterhouse, D. M., Lin, I., Morrison, L., Émond, B., Lafeuille, M., Wang, Y., Díaz, L., Lefèbvre, P., & Waters, D. D. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04334-8
Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC
Kim, J., Park, G., Park, S., Jung, H. A., Lee, S.-H., Ahn, J. S., Ahn, M., & Sun, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1827867
BATPC: A biology-anchored tumor progression classification for interpreting multidimensional progression phenotypes across solid tumors
Gupta, Y. K. (2026) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2026.101316
New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer
Zullo, L., & Remón, J. (2026) · Cancers · doi:10.3390/cancers18142334
Prevalence of uncommon epidermal growth factor receptor (EGFR) Mutations in Non-Small Cell Lung Carcinoma (NSCLC): A tertiary cancer care center experience
Bhattacharjee, C., Sabnam, S., Banerjee, S., Saha, K., Roy, S., Vinarkar, S., Parihar, M., Roy, S., & Mishra, D. K. (2026) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1710_25
Baseline Uncommon EGFR Mutations in Non–Small-Cell Lung Cancer: Structure–Function Classification and Clinical Evidence Interpretation
Yang, S., Ma, X., Zhao, Y., & Ma, J. (2026) · Cancer Control · doi:10.1177/10732748261481943
EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib
Zhang, J., Cui, Y., Ren, Q., Wu, X., Li, J., Liu, X., Zhang, B., & Yue, D. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04583-3
BindingDB Entry 50020306: Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.
BindingDB (2024) · UC San Diego · doi:10.7270/q2cv4p5p
BindingDB Entry 50009645: Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
BindingDB (2021) · UC San Diego · doi:10.7270/q21v5jfw
BindingDB Entry 50018925: Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2.
BindingDB (2024) · UC San Diego · doi:10.7270/q25d8x2d

Authors: Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A.
Affiliations: Brigham and Women's Hospital (US)
Dana-Farber Cancer Institute (US)
Corresponding author: Oxnard, Geoffrey R.
ORCID: Oxnard, Geoffrey R.
Nishino, Mizuki
Dahlberg, Suzanne E.
Lindeman, Neal I.
Butaney, Mohit
Johnson, Bruce E.
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2013-02
Volume: 8
Issue: 2
Pages: 179-184
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0b013e3182779d18
PMC: PMC3549533
OpenAlex: W2075445339
Cited by: 360
References: 32
Citations by year: 2026: 17 · 2025: 30 · 2024: 33 · 2023: 41 · 2022: 50 · 2021: 36 · 2020: 31 · 2019: 26 · 2018: 24 · 2017: 19 · 2016: 16 · 2015: 15 · 2014: 15 · 2013: 7
FWCI: 14.35
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1034 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5k23ca157631-02)
National Cancer Institute (K23-CA157631, P50CA090578, R01CA135257)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: EGFR exon 20 insertion, non-small cell lung cancer, lung adenocarcinoma, EGFR mutation, EGFR tyrosine kinase inhibitors, survival, never smokers, Asian patients, targeted therapy, molecular properties
MeSH terms: Adult, Aged, Aged, 80 and over, Amino Acid Sequence, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Exons, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Mutagenesis, Insertional, Sequence Homology, Amino Acid, Young Adult, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks